• Join
  • Login
  • Contact

Search abstracts / presentations

In silico design and validation of novel cyclin dependent kinase (DC) receptor inhibitors, using the palbociclib scaffold as a lead for the management of breast cancer

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: APS-080
  • By: SHOEMAKE, Claire ()
  • Co-author(s): Mr Andrew Felice, Pharmacy
    Dr Claire Shoemake, Senior Lecturer
  • Abstract:

    Palbociclib has been shown to disrupt tumour proliferation in locally advanced and metastatic breast cancer by inhibiting activity propagated by the homologous enzymes Cyclin Dependent Kinase receptors 4 and 6 (CDK4/6). Despite the therapeutic and prognostic effectiveness of Palbociclib, research shows that prolonged periods of exposure to

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses